Search results
Results from the WOW.Com Content Network
Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. [5] It is delivered subcutaneously either by injection or from an insulin pump .
Eli Lilly and Company developed and marketed the first rapid-acting insulin analogue (insulin lispro rDNA) Humalog. It was engineered through recombinant DNA technology so that the penultimate lysine and proline residues on the C-terminal end of the B-chain were reversed.
The lower-priced version of Humalog Mix75/25 will be known as Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen (100 units/mL) while that of Humalog Junior KwikPen ...
Eli Lilly's (LLY) insulin candidate, Ultra Rapid Lispro, meets primary endpoint of two late- stage studies in type I and type II diabetes patients of non-inferiorly to Humalog.
1983 Eli Lilly and Company produces biosynthetic human insulin with recombinant DNA technology, Humulin; 1985 Axel Ullrich sequences a human cell membrane insulin receptor. 1988 Novo Nordisk produces recombinant biosynthetic human insulin; 1996 Lilly Humalog "lispro" insulin analogue approved.
The shortage applies to the company's 10 mL vials of Humalog and Insulin Lispro Injection medications. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290 ...
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify
Drugmaker Eli Lilly warned this week that two of its formulations of insulin would be temporarily out of stock through the beginning of April, citing a “brief delay in manufacturing.”